阿帕替尼联合替吉奥对一线治疗失败晚期胃癌患者疾病控制及预后影响

Effect of apatinib combined with tegafur on disease control and prognosis in patients with advanced gastric cancer who failed first-line therapy

目的:分析阿帕替尼联合替吉奥对一线治疗失败晚期胃癌患者疾病控制及预后影响。方法:选取2016年2月至2018年2月72例一线治疗失败的晚期胃癌患者作为研究对象,随机分为观察组和对照组;观察组患者给予阿帕替尼联合替吉奥治疗,对照组患者仅给予阿帕替尼治疗;比较两组患者的临床疗效、无进展生存时间、存活时间及不良反应发生率。结果:观察组患者的临床疗效总缓解率、疾病控制率分别为30.56%、69.44%,高于对照组的11.11%、41.67%(P<0.05);观察组患者的FPSmax为6.9个月、FPSmin为4.2个月,FPS中位为5.2个月;对照组患者的FPSmax为6.3个月、FPSmin为4.0个月,FPS中位为4.9个月,经Log-rank检验,观察组患者的FPS较对照组延长(χ^2=6.045,P=0.014);观察组患者的生存时间max为13.5个月、生存时间min为4.2个月,生存时间中位为9个月,对照组患者的生存时间max为12.5个月、生存时间min为4.0个月,生存时间中位为6.5个月,经Log-rank检验,观察组患者的生存时间较对照组延长(χ^2=7.958,P=0.005);观察组患者的不良反应发生率为8.33%,低于对照组患者的27.78%(P<0.05)。结论:阿帕替尼联合替吉奥治疗一线治疗失败的晚期胃癌患者可提高疾病控制率,延长无进展生存时间和存活时间,为晚期胃癌患者二线治疗提供新参考。

Objective:To investigate the effect of apatinib combined with tegafur on disease control and prognosis in patients with advanced gastric cancer who failed first-line therapy.Methods:seventy-two patients with advanced gastric cancer who failed first-line treatment from February 2016 to February 2018 were selected and divided into observation group and control group randomly.The observation group was treated with apatinib and tegafur,and the control group was treated with only apatinib to compare the clinical efficacy,progression-free survival time,survival time and incidence of adverse reactions between the two groups.Result:The overall response rate and disease control rate of the observation group were 30.56%and 69.44%,respectively,which were significantly higher than those of the control group 11.11%and 41.67%(P<0.05).The observation group had FFSmax of 6.9 months and FPSmin of 4.2 months.The median FPS was 5.2 months.The FFSmax of the control group was 6.3 months,the FPS min was 4.0 months,and the median FPS was 4.9 months.After the Log-rank test(χ^2=6.045,P=0.014),the FPS of the observation group was significantly higher than that of the control group.Prolonged,observation group max survival time 13.5 months,min survival time 4.2 months,median survival time 9 months,control group survival time max 2.5 months,survival time min4.0 months,survival time median after 6.5 months.After Log-rank test(χ^2=7.958,P=0.005),the survival time of the observation group was significantly longer than that of the control group.The incidence of adverse reactions in the observation group was only 8.33%,which was significantly lower than that of the control group(27.8%)(P<0.05).Conclusion:Apatinib combined with tiggio treatment for first-line treatment failure of advanced gastric cancer patients can improve disease control rate,prolong progression-free survival time and survival time,and provide a new reference for second-line treatment of patients with advanced gastric cancer.